RAC1 as a novel therapeutic target for acute liver failure

Acute liver failure (ALF) is a life-threatening condition characterized by severe inflammation and oxidative stress for which there are limited treatment options. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF. RAC1-targeted therapy merits further studies in clinical settings.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-08-11
DOI
https://doi.org/10.1016/j.jhepr.2025.101547
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

RAC1 as a novel therapeutic target for acute liver failure

Ali Canbay, Andrea A. Barquero, Bárbara Bueloni, Julieta Comin et al.
JHEP Reports
Liver Disease Diagnosis and Treatment
article

RAC1 as a novel therapeutic target for acute liver failure

Ali Canbay, Andrea A. Barquero, Bárbara Bueloni, Julieta Comin, Esteban Fiore, María José Cantero, Catalina Atorrasagasti, Martín Fauda, Guillermo Mazzolini, Lucia Gandolfi Donadío, Juan Bayo, Lucia Lameroli, Francisco Alejandro González Orozco, Matias S Ciarlantini, Daiana Ganiewich
article en

Abstract

Acute liver failure (ALF) is a life-threatening condition characterized by severe inflammation and oxidative stress for which there are limited treatment options. Our study provides strong scientific justification for targeting the RAC1 protein, demonstrating that its pharmacological inhibition with 1D-142 reduces liver injury, immune cell infiltration, and oxidative damage in murine models of ALF and in human liver explants. These findings identify RAC1 as a novel therapeutic target and provide translational support for its potential clinical application in ALF. RAC1-targeted therapy merits further studies in clinical settings.

JHEP ReportsVol. 7(11)
Consejo Nacional de Investigaciones Científicas y Técnicas (AR), Austral University (AR), Universidad de Buenos Aires (AR), Fundación Instituto Leloir (AR), National Institute of Industrial Technology (AR), Centro Científico Tecnológico - San Juan (AR), Hospital Universitario Austral (AR), Spectrum Research (United States) (US), Fundación Ciencias Exactas y Naturales (AR), Ruhr University Bochum (DE)
Good health and well-being
Openalex Percentile: Top 71%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

RAC1 as a novel therapeutic target for acute liver failure — Ali Canbay, Andrea A. Barquero, et al. · JHEP Reports (2025) | TGRS Research Map | TGRS